The 2026 Healthtech Messaging Index
Proscia
proscia.com·scored September 1, 2026
23/38
Approaching
Close. The bones are good. A few targeted fixes on the weakest signals would push Proscia into magnetic territory.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Digital pathology AI platform for clinical diagnostics and biopharma drug development, it named:
Buyer we put in the prompt: Pathologist, Digital Pathology Lab Director, or VP of Translational Medicine at a top-20 pharma company or large diagnostic laboratory. Both the buyer and the category were inferred from Proscia’s homepage alone. The model had no web access.
Proscia was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI mentioned you for "Digital pathology AI platform for clinical diagnostics and biopharma drug development", but only generically: "Proscia offers a digital pathology platform called Concentriq aimed at both biopharma research workflows and clinical diagnostics, with a focus on AI integration and enterprise scalability.". You're on the radar, but AI doesn't yet repeat your specific positioning back.
Overall assessment
Proscia's biggest strength is its proof stack: KLAS #1 in two geographies, FDA clearance, five concrete scale statistics, and four named customer testimonials with titles ... rare credibility for a regulated niche. The biggest gap is the complete absence of problem-led narrative and cost-of-inaction framing; the page never articulates what pain pathologists or biopharma teams suffer today, making it a capability brochure rather than a persuasive story that drives urgency to act.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
05Problem Leadership
“No problem-first framing exists on the page; hero leads with "Intelligence for the Decisions that Matter Most.”
The page opens with a solution-and-aspiration headline, not a buyer problem statement ... there is no moment where Proscia names the pain a pathologist or biopharma team is experiencing before pitching Concentriq.
All 19 signals, scored 0 to 2.
Total 23/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Intelligence for the Decisions that Matter Most" / "Pathology's AI platform for the experts answering medicine's biggest questions”
The hero communicates the domain (pathology) and audience (pathology experts) but 'decisions that matter most' is vague aspiration ... a stranger can't instantly grasp the specific problem solved or Proscia's point of view without reading further.
- 1
02Rebellion / Movement
“a pathology platform with AI bolted on can't keep up”
There is one buried line pushing against bolt-on AI, but no named enemy, no named status quo pattern, and no sustained rebellious POV ... it appears once in a webinar blurb, not as a defining narrative thread.
- 2
03Owned Language & Category
“Concentriq" / "computational pathology" / "Pathology AI for Precision Medicine" / "Concentriq Fifth Generation”
Proscia owns the named platform brand 'Concentriq,' uses 'Concentriq Fifth Generation' as a versioned product frame, and explicitly claims the category 'Pathology AI for Precision Medicine' ... specific enough for an AI to quote and attribute uniquely.
- 1
04ICP Clarity
“Clinical LAB SOLUTIONS" and "Life Sciences SOLUTIONS" / "experts answering medicine's biggest questions”
Two verticals (clinical labs and life sciences/biopharma) are named but role specificity is weak ... no mention of pathologist title, lab size, budget authority, or company stage that would let a visitor self-qualify instantly.
- 0
05Problem Leadershipweakest
“No problem-first framing exists on the page; hero leads with "Intelligence for the Decisions that Matter Most.”
The page opens with a solution-and-aspiration headline, not a buyer problem statement ... there is no moment where Proscia names the pain a pathologist or biopharma team is experiencing before pitching Concentriq.
- 2
06Solution Clarity
“powers precision medicine from discovery through diagnosis, with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review”
After reading the Concentriq section a visitor can repeat the one-sentence summary accurately ... the use cases are named concretely and the scope (discovery through diagnosis) is clear.
- 0
07Cost of Inaction
“No cost-of-inaction language anywhere on the page.”
The page never names what happens if a lab or biopharma company keeps doing things the old way ... no lost time, failed trials, misdiagnoses, or competitive disadvantage is articulated.
- 1
08Promised Land
“Turn tissue into biomarker insights, move therapies through development and get them to the patients who need them”
There is a directional 'after' state for life sciences but it stays at the level of aspiration rather than painting a specific, vivid operational outcome the buyer will live in post-adoption.
Trust Signal
4 signals
- 2
09Proof & Evidence
“12M cases managed annually" / "4,000+ hospitals and clinics" / "16 of 20 top pharmaceutical companies" / "30,000+ studies" / "100% of customers told KLAS they would buy Concentriq again”
The stats section delivers five concrete, specific numbers with named sources (KLAS), giving buyers real scale evidence rather than adjective-heavy claims.
- 2
10Social Proof
“Dr. Luis Cano, Dr. Cherub Kim (Labcorp), Dr. Amanda Hemmerich (IQVIA Laboratories), Dr. Derrick Forchetti (South Bend Medical Foundation)”
Four named testimonials with full titles and affiliated organizations, plus a logo wall of recognizable enterprise names including Cleveland Clinic, Bayer, and Bristol Myers Squibb ... strong social proof execution.
- 2
11Authority & Credibility
“Best in KLAS 2026" / "Concentriq is the highest-rated digital pathology platform in both the United States and Europe" / "FDA 510(k) Clearance”
KLAS #1 ranking in two geographies, FDA regulatory clearance with a named plan (PCCP), and a named video series (Feats of Strength) all constitute demonstrated third-party authority rather than self-claimed superlatives.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or the 'do nothing' option anywhere on the page.”
The page never acknowledges what buyers might be doing instead ... no incumbent vendors named, no manual-slide-review alternative addressed, no 'do nothing' cost discussed.
AI Signal
6 signals
- 1
13Customer Focus
“Behind every successful digital pathology deployment is a pathologist or lab leader who broke down barriers" (Feats of Strength section)”
The Feats of Strength section briefly centers customer protagonists, but the rest of the page ... hero, stats, product sections ... tilts toward Proscia's capabilities and platform, making the overall narrative mixed.
- 1
14AI-Parmesan Index
“Pathology's AI platform" / "enterprise AI layer at its core" / "computational pathology is essential”
AI is central to the narrative and the page gestures at mechanism ('enterprise AI layer at its core') but never explains how the AI works, what models power it, or what specific outputs it produces ... present but not mechanistic enough to score 2.
- 2
15LLM Quotability
“16 of the top 20 pharma companies and over 4,000 hospitals and clinics globally" / "100% of customers told KLAS they would buy Concentriq again”
Several declarative, statistic-laden sentences are clean and specific enough for an LLM to lift verbatim as evidence when recommending Proscia in a category comparison.
- 1
16Copyright Freshness
“Best in KLAS 2026" / blog post on Kary Rogers with no visible date in scraped content”
The KLAS 2026 badge signals recency, but no explicit publication dates are visible on blog or press release cards in the scraped content, leaving recency signals partial.
- 2
17Entity Distinctiveness
“Concentriq Fifth Generation" / "FDA 510(k) Clearance" / "Best in KLAS 2026 in both the United States and Europe" / "16 of 20 top pharma”
The combination of a named versioned platform, dual-geography KLAS #1, FDA clearance with PCCP, and the 'Feats of Strength' branded series makes Proscia unmistakably distinct ... an AI could not confuse this description with a generic competitor.
- 1
18AI Recommendation Check
“AI named you alongside Proscia, Paige.AI, PathAI, Hamamatsu (NDP.serve), Leica Biosystems (Aperio), describing you as: "Proscia offers a digital pathology platform called Concentriq aimed at both biopharma research workflows and clinical diagnostics, with a focus on AI integration and enterprise scalability.".”
AI mentioned you for "Digital pathology AI platform for clinical diagnostics and biopharma drug development", but only generically: "Proscia offers a digital pathology platform called Concentriq aimed at both biopharma research workflows and clinical diagnostics, with a focus on AI integration and enterprise scalability.". You're on the radar, but AI doesn't yet repeat your specific positioning back.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“EXPLORE CONCENTRIQ" CTA / "READ THE KLAS REPORT" / "SEE THEIR STORIES" / "Save my spot”
Multiple CTAs exist but they scatter attention across four competing actions with no numbered process or clear primary/secondary hierarchy ... there is no visible 'here's how to get started in 3 steps' path connecting to one dominant CTA.
Keep the lead
AI already names Proscia. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Proscia the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.